Showing 1591-1600 of 2152 results for "".
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Patricia Bath, MD, Inducted Into National Inventors Hall of Famehttps://modernod.com/news/patricia-bath-md-inducted-into-national-inventors-hall-of-fame/2480295/Patricia Bath, MD, was among seven innovation pioneers inducted into the National Inventors Hall of Fame (NIHF) Dr. Bath, who was inducted posthumously, contributed to the invention of laserphaco, allowing surgeons to use ultrasound to perform all steps of cataract r
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- EyePoint Pharmaceuticals Forms Executive Scientific Advisory Boardhttps://modernod.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital. Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. B
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r